173 related articles for article (PubMed ID: 20217604)
1. Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes.
Rothdiener M; Beuttler J; Messerschmidt SK; Kontermann RE
Methods Mol Biol; 2010; 624():295-308. PubMed ID: 20217604
[TBL] [Abstract][Full Text] [Related]
2. Targeting of nanoparticles: folate receptor.
Kularatne SA; Low PS
Methods Mol Biol; 2010; 624():249-65. PubMed ID: 20217601
[TBL] [Abstract][Full Text] [Related]
3. Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling.
Messerschmidt SK; Kolbe A; Müller D; Knoll M; Pleiss J; Kontermann RE
Bioconjug Chem; 2008 Jan; 19(1):362-9. PubMed ID: 17988079
[TBL] [Abstract][Full Text] [Related]
4. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
5. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
6. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
7. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery.
Lu RM; Chang YL; Chen MS; Wu HC
Biomaterials; 2011 Apr; 32(12):3265-74. PubMed ID: 21306768
[TBL] [Abstract][Full Text] [Related]
8. Building and characterizing antibody-targeted lipidic nanotherapeutics.
Kirpotin DB; Noble CO; Hayes ME; Huang Z; Kornaga T; Zhou Y; Nielsen UB; Marks JD; Drummond DC
Methods Enzymol; 2012; 502():139-66. PubMed ID: 22208985
[TBL] [Abstract][Full Text] [Related]
9. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells.
Simard P; Leroux JC
Int J Pharm; 2009 Nov; 381(2):86-96. PubMed ID: 19446624
[TBL] [Abstract][Full Text] [Related]
10. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.
Dinauer N; Balthasar S; Weber C; Kreuter J; Langer K; von Briesen H
Biomaterials; 2005 Oct; 26(29):5898-906. PubMed ID: 15949555
[TBL] [Abstract][Full Text] [Related]
11. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes.
Schnyder A; Krähenbühl S; Török M; Drewe J; Huwyler J
Biochem J; 2004 Jan; 377(Pt 1):61-7. PubMed ID: 14516278
[TBL] [Abstract][Full Text] [Related]
12. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
Demirgöz D; Garg A; Kokkoli E
Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096
[TBL] [Abstract][Full Text] [Related]
13. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
Messerschmidt SK; Musyanovych A; Altvater M; Scheurich P; Pfizenmaier K; Landfester K; Kontermann RE
J Control Release; 2009 Jul; 137(1):69-77. PubMed ID: 19306900
[TBL] [Abstract][Full Text] [Related]
14. In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes.
Rüger R; Tansi FL; Rabenhold M; Steiniger F; Kontermann RE; Fahr A; Hilger I
J Control Release; 2014 Jul; 186():1-10. PubMed ID: 24810115
[TBL] [Abstract][Full Text] [Related]
15. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
McNeeley KM; Karathanasis E; Annapragada AV; Bellamkonda RV
Biomaterials; 2009 Aug; 30(23-24):3986-95. PubMed ID: 19427688
[TBL] [Abstract][Full Text] [Related]
16. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
17. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
Rabenhold M; Steiniger F; Fahr A; Kontermann RE; Rüger R
J Control Release; 2015 Mar; 201():56-67. PubMed ID: 25617725
[TBL] [Abstract][Full Text] [Related]
18. Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro.
Moradpour D; Compagnon B; Wilson BE; Nicolau C; Wands JR
Hepatology; 1995 Nov; 22(5):1527-37. PubMed ID: 7590672
[TBL] [Abstract][Full Text] [Related]
19. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system.
Kakudo T; Chaki S; Futaki S; Nakase I; Akaji K; Kawakami T; Maruyama K; Kamiya H; Harashima H
Biochemistry; 2004 May; 43(19):5618-28. PubMed ID: 15134436
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
